Thoratec Corporation

Skip to content

Overview

THOR (Common Stock)
Price32.91Change+ 0.10
Volume358,970% Change0.30%
12/26/2014 4:00 p.m. ETPricing delayed 20 minutes

Thoratec is the world leader in mechanical circulatory support with the broadest product portfolio to treat the full range of clinical needs for patients suffering from advanced heart failure. The company's products include the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag and PediMag / PediVAS product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit www.thoratec.com.

Recent News

More >>
DateTitle 
12/01/14Thoratec Announces Completion Of Enrollment In The HeartMate III™ CE Mark Trial
PLEASANTON, Calif., Dec. 1, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced completion of enrollment in the HeartMate III CE Mark trial.  This trial enrolled a total of 50 patients at ten sites across Europe, Canada, and Australia. "We are very pleased with the rapid completion of enrollment in the HeartMate III CE Mark study, marking a significant cl... 
Printer Friendly Version
11/26/14Thoratec Announces Presentations At Investor Conferences For December 2014
PLEASANTON, Calif., Nov. 26, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences. On Tuesday, December 2, the company will participate in the 26th Annual Piper Jaffray Healthcare Conference.  D. Keith Grossman, President and Chief Executive Officer, will provide an update on the company beginning at ... 
Printer Friendly Version
11/06/14Thoratec Announces Presentations At Investor Conferences For November 2014
PLEASANTON, Calif., Nov. 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences. On Wednesday, November 12, the company will participate in the Credit Suisse 2014 Healthcare Conference.  D. Keith Grossman, President and Chief Executive Officer, will provide an update on the company beginning at 10:00... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.